Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives
Novel tricyclic heterocyclic sulfonamide derivatives and sulfonic ester derivatives which have excellent antitumor activity and are represented by the following general formula (I) and processes for producing the same are provided. The present sulfonamide derivatives or a sulfonic ester derivatives are represented by the following general formula (I): ##STR1## wherein G represents an aromatic 5- or 6-membered ring; L represents 0 or --N(R.sup.1)-- and --R.sup.1 represents hydrogen or lower alkyl; and M represents a tricyclic structure selected from among the following; ##STR2## rings A and B each represent an unsaturated 5- or 5 -membered ring; X represents N(R.sup.2) wherein R.sup.2 represents hydrogen or lower alkyl, or NHCO; Y represents 0, S(O).sub.n, C(R.sup.3) (R.sup.4), C(O), N(R.sup.5), CH(R.sup.6)CH(R.sup.7), C(R.sup.8).dbd.C(R.sup.9), N(R.sup.10) C(O), N.dbd.CR.sup.11), OCH(R.sup.12), S(O).sub.n CH(R.sup.13) or N(R.sup.14)CH(R.sup.15); Z represents nitrogen or C(R.sup.16); and n represents 0, 1 or 2, R.sup.3 to R.sub.13, R.sup.15 and R.sup.16 each represent hydrogen or lower alkyl, and R.sup.14 represents hydrogen, lower alkyl or lower acyl.
Latest Eisai Co., Ltd. Patents:
- HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER
- Hemiasterlin derivatives and uses thereof in the treatment of cancer
- MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS
- Macrocyclic compounds useful as pharmaceuticals
- HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER
Claims
1. A compound represented by the following formula (I) or a pharmacologically acceptable salt thereof: ##STR85## wherein G represents an aromatic 5- or 6-membered ring having 1 or 2 substituents, said substituents each being selected from the group consisting of a halogen atom, a linear or branched C.sub.1 -C.sub.6 alkyl group, a linear or branched C.sub.1 -C.sub.6 alkoxy group, and an amino group optionally substituted by linear or branched C.sub.1 -C.sub.6 alkyl groups;
- L represents oxygen or --N(R.sup.1)--, wherein R.sup.1 represents hydrogen or lower alkyl; and
- M represents ##STR86## which fused phenyl rings can be optionally substituted with one or more substituents selected from the group consisting of a halogen atom, a linear or branched C.sub.1 -C.sub.6 alkyl group optionally substituted by a hydroxy group, a linear or branched C.sub.1 -C.sub.6 alkoxy group optionally substituted by a hydroxy group, a hydroxy group, an amino group optionally substituted by linear or branched C.sub.1 -C.sub.6 alkyl groups optionally having a hydroxy group, C.sub.1 -C.sub.4 acyl groups, a cyano group and an oxo group; and
- X represents --N(R.sup.2)--, wherein R.sup.2 represents hydrogen or lower alkyl, or --NHCO--
- provided that a combination wherein G is 4-methylphenyl or 4-methoxycarbonylaminophenyl, and X is --N(R.sup.2)-- is excluded therefrom.
2. The compound or a pharmacologically acceptable salt thereof as set forth in claim 1 wherein G is lower alkoxyphenyl.
3. The compound or a pharmacologically acceptable salt as set forth in claim 1 wherein L is NH.
4. The compound or a pharmacologically acceptable salt thereof as set forth in claim 1 wherein G is 4-methoxyphenyl.
5. A process for producing a compound or a pharmaceologically acceptable salt thereof as set forth in claim 1 comprising reacting a sulfonic acid represented by the following general formula (II):
- Gb represents optionally protected G as defined in claim 1; or a reactive derivative thereof with a compound represented by the following general formula (III):
- L has the same meaning as the one defined in claim 1; and
- Ma represents optionally protected M as defined in claim 1;
- and optionally removing the protecting group(s) of G, if any, of the product thus obtained.
6. A medicinal composition comprising an effective anti-tumor amount of a compound as set forth in claim 1, and a pharmacologically acceptable filler.
7. A method of treating nasopharyngeal cancer, pulmonary cancer, intestinal cancer, mammary cancer, uterus cancer, gastric cancer, ovarian cancer and liver cancer, comprising:
- administering to a patient in need thereof, an effective anti-tumor amount of a compound or a pharmacologically acceptable salt thereof as set forth in claim 1.
8. A compound as set forth in claim 1, wherein G represents ##STR87## R.sup.31 represents hydrogen, halogen, lower alkyl, lower alkoxy, nitro, cyano or amino optionally substituted by lower alkyl;
- R.sup.32 and R.sup.33 are the same or different from each other and each represents hydrogen, lower alkyl, lower alkoxy or halogen.
| 0215200 | March 1987 | EPX |
| 472053A2 | February 1992 | EPX |
| 0433093 | February 1943 | JPX |
- Bailey et al., Tetrahedron Letters, vol. 34, pp. 2979-2982, 1970. Bailey et al., J. of the chemical Soc., Perkins Trans. 1, vol. 17, pp. 1809-1818, 1973. Mahboobi et al. Arch. Pharm. (Weinheim) 327, 611-617, 1994. R.M. Acheson, The Chemistry of Heterocyclic Compounds (1956), Ch. III, V. 9:105-147. G.P. Ellis, The Chemistry of Hetercyclic Compounds (1987), V.9. G.P. Ellis, The Chemistry of Heterocyclic Compounds (1992), V.47, Part 2. Capps et al., J. Med. Chem. (1992), V.35:4770-4778. Boothroyd et al., J. Chem. Soc. (1953), Section 306, Part II, pp. 1504-1509. Nodiff et al., J. Org. Chem. (1959), V.25:60-65. Mital et al., J. Chem. Soc. (C) (1969), pp. 2148-2151. Bendall et al., Aust. J. Chem. (1972), V.25:2451-2465. Davy et al., Chemistry and Industry (1985), pp. 824-827. Maller et al., J. of Labelled Compounds and Radiopharmaceuticals, V.XX, No. 12, pp. 1339-1349. Abdel-Hamid, Effect of Some New Uracil Der . . . , Egypt. J. Pharm. 34 (1-3) 67, 1993. Fathalia, Biological Activity of Some New Uracil Der . . . , Bull. Natl. Res. Cent. 18 (1) p. 55, 1993. Shirai H., Synthesis of 1 Amino . . . , NSDYAI (18), pp. 77-78, 1970. Chemical Abstract 122:23305, Abdel-Hamid, "Effect of Some New Uracil Der . . . ", Egypt. J. Pharm. 34 (1-3) 67 (1993). Chemical Abstract 120:208026, Fathalia, "Biological Activity of Some New Uracil Der . . . ", Bull. Natl. Res. Cent. 18 (1) p. 55 (1993).
Type: Grant
Filed: Dec 5, 1996
Date of Patent: Dec 29, 1998
Assignee: Eisai Co., Ltd. (Tokyo)
Inventors: Hiroshi Yoshino (Chiba), Norihiro Ueda (Ibaraki), Jun Niijima (Ibaraki), Toru Haneda (Ibaraki), Yoshihiko Kotake (Ibaraki), Kentaro Yoshimatsu (Ibaraki), Tatsuo Watanabe (Chiba), Takeshi Nagasu (Ibaraki), Naoko Tsukahara (Chiba), Nozomu Koyanagi (Ibaraki), Kyosuke Kitoh (Ibaraki)
Primary Examiner: Mukund J. Shah
Assistant Examiner: Bruck Kifle
Law Firm: Birch, Stewart, Kolasch & Birch, LLP
Application Number: 8/760,738
International Classification: A61K 3144; A61K 3140; C07D22106; C07D20982;
